Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02352766 · ClinicalTrials.gov registry record
Role of NGS-based ThyroSeq Panel in Cancer Diagnosis in Thyroid Nodules
A clinical trial, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 256
- Enrollment target
NCT02352766 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 256 participants.
The verdict
NCT02352766 has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 256 participants
- Enrollment target
Study Summary
Recently, targeted next generation sequencing (NGS) platforms have been introduced that allow inexpensive testing for hundreds of mutational hotspots at the same time. A number of additional mutational markers in thyroid cancer have been identified. Highly promising markers associated with tumor prognosis have also been found. This multi-institutional study aims to validate the diagnostic use of mutational markers in thyroid nodules with indeterminate cytology. The proposed hypothesis is that a broad NGS-based genotyping of thyroid nodules using a large panel of mutational markers applied to thyroid FNA samples can provide an accurate cancer risk stratification in thyroid nodules. The performance of the panel will be tested in a multi-institutional double-blind prospective study of FNA samples from thyroid nodules with indeterminate cytology and available surgical outcome
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2015-01 |
| Est. Completion | 2019-02-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02352766
The ClinicalTrials.gov registry entry for NCT02352766 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 256 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02352766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02352766 about?
NCT02352766 is a clinical study titled "Role of NGS-based ThyroSeq Panel in Cancer Diagnosis in Thyroid Nodules". Recently, targeted next generation sequencing (NGS) platforms have been introduced that allow inexpensive testing for hundreds of mutational hotspots at the same time. A number of additional mutational markers in thyroid cancer have been identified. Highly promising markers associated with tumor pro...
What is the current status of trial NCT02352766?
This trial is currently completed. The enrollment target is 256 participants. The study started on 2015-01. Estimated completion is 2019-02-15.
Who is sponsoring clinical trial NCT02352766?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.